Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199194 | 0.88 | HTR7 (0.48) | HTR7ALDH1A1L3MBTL1SIGMAR1 | |
| SCHEMBL3230830 | 0.84 | MEN1 (0.52) | HTR7L3MBTL1LMNASIGMAR1 | |
| Hydrochloric Acid SCHEMBL2387381 | 0.82 | MEN1 (0.51) | HTR7L3MBTL1LMNASIGMAR1 | |
| SCHEMBL31606858 | 0.81 | LMNA (0.54) | ADRA2CALDH1A1SRCNR1H2KAT2B | |
| SCHEMBL13607115 | 0.79 | HTR7 (0.47) | HTR7ALDH1A1SRCL3MBTL1KAT2B | |
| SCHEMBL13591868 | 0.76 | L3MBTL1 (0.73) | ALDH1A1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL4196076 | 0.76 | ALDH1A1 (0.53) | ALDH1A1LMNASIGMAR1SMN1; SMN2 | |
| SCHEMBL18977175 | 0.76 | CARM1 (0.49) | ADRA2CALDH1A1LMNACARM1PRMT6 | |
| SCHEMBL5903459 | 0.75 | NPC1 (0.53) | HTR7ALDH1A1L3MBTL1LMNA | |
| SCHEMBL25438515 | 0.75 | TNIK (0.40) | ADRA2CSRCKAT2BLMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2029145-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | HTR7 4109/4885ADRA2C 4580/4885ALDH1A1 1780/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | HTR7 4109/4885ADRA2C 4580/4885ALDH1A1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.